Evidence map›Paper›PMID 31034206›Full record

ArticleAnalytical chemistry2019

Development of a New Tandem Ion Exchange and Size Exclusion Chromatography Method To Monitor Vaccine Particle Titer in Cell Culture Media.

Andrew W Shaddeau, Nicole A Schneck, Yile Li, Vera B Ivleva, Frank J Arnold, Jonathan W Cooper, Q Paula Lei

Open access · greenAbstract read
In one paragraph

Article in Analytical chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. A Microfluidic Dual-Aptamer Sandwich Assay for Rapid and Cost-Effective Detection of Recombinant Proteins.Microchemical journal : devoted to the application of microtechniques in all branches of science · 2023
    Article
  4. Vaccine delivery systems toward lymph nodes.Advanced drug delivery reviews · 2021
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Andrew W ShaddeauVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Nicole A SchneckVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Yile LiVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Vera B IvlevaVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Frank J ArnoldVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Jonathan W CooperVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.
Q Paula LeiVaccine Production Program, Vaccine Research Center , National Institute of Allergy and Infectious Diseases, National Institutes of Health , Gaithersburg Maryland United States.ORCID 0000-0002-3656-4014
National Institutes of Health · US

Funding

Production of a Broadly Neutralizing HIV Antibody (VRC01)ZIBAI005121 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALL, JASON · 2011 to 2025
$159.0M
Development/production of universal influenza vaccinesZIBAI005109 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GALL, JASON · 2010 to 2025
$155.8M
Intramural NIH HHS Z99 AI999999
6 · The paper itself

Abstract

A new tandem chromatography method was developed to directly measure the titers of various vaccine candidate molecules in cell culture without a prior purification step. The method utilized a strong anion exchange chromatography (IEC) column in tandem with a size exclusion chromatography (SEC) column to efficiently separate the nanoparticle and virus-like particle (VLP) vaccine molecules from host cell proteins and other components in the cell culture media. The dual (charge and hydrodynamic size) separation mode was deemed necessary to achieve good separation of the vaccine product for quantitation. The method development and quality assessment illustrated herein was focused on the influenza vaccine candidate H1ssF, a hemagglutinin (group 1) stabilized stem molecule fused to ferritin to form nanoparticles. This newly established method was then successfully applied to several vaccine candidate developmental projects, such as the hemagglutinin-ferritin (HAF) nanoparticle and encephalitic alphavirus VLP-based vaccines. This IEC-SEC strategy was established as a platform approach for direct titer measurement of novel vaccine molecules in cell culture.

Indexed as

AnimalsCell LineChromatography, GelChromatography, Ion ExchangeCulture MediaMammalsParticle SizeVaccinesCulture MediaVaccines

Identifiers

PMID31034206
PMCPMC11040568
OpenAlexW2942736834

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.